RPID Files Routine 8-K, Confirms Registration Details

TL;DR

**RPID filed a standard administrative 8-K, no new news.**

AI Summary

This 8-K filing from RAPID MICRO BIOSYSTEMS, INC. (RPID) on January 10, 2024, is a routine administrative update. It confirms the company's current registration details, including its address at 1001 Pawtucket Boulevard West, Suite 280, Lowell, MA 01854, and its Class A Common Stock trading on The Nasdaq Global Select Market under the symbol RPID. This filing is primarily informational and does not contain new financial results or significant operational changes, meaning it has minimal direct impact on current or prospective shareholders.

Why It Matters

This filing is largely administrative, confirming basic company information. It doesn't contain new financial data or strategic announcements, so it has little immediate impact on the stock's valuation or investor decisions.

Risk Assessment

Risk Level: low — This 8-K is a routine administrative filing and does not disclose any new risks or material changes to the company's operations or financial condition.

Analyst Insight

Investors should note this is a standard administrative filing with no new material information. No immediate action is required based on this specific 8-K, but it confirms the company's current public registration details.

Key Players & Entities

• RAPID MICRO BIOSYSTEMS, INC. (company) — the registrant filing the 8-K
• RPID (company) — the trading symbol for Class A Common Stock
• The Nasdaq Global Select Market (company) — the exchange where RPID's stock is registered
• January 10, 2024 (date) — date of earliest event reported and filing date
• 1001 Pawtucket Boulevard West, Suite 280, Lowell, MA 01854 (address) — principal executive offices of the registrant
• 978-349-3200 (phone_number) — registrant's telephone number
• 001-40592 (number) — Commission File Number

FAQ

Key Financial Figures

• $0.01 — which registered Class A Common Stock, $0.01 par value per share RPID The Nasdaq Glo
• $6.2 million — rently expects total revenue of between $6.2 million and $6.4 million in the fourth quarter
• $6.4 million — tal revenue of between $6.2 million and $6.4 million in the fourth quarter of 2023, represen
• $22.4 million — total revenue is expected to be between $22.4 million and $22.6 million, representing growth
• $22.6 m — xpected to be between $22.4 million and $22.6 million, representing growth of over 30%
• $95 million — revenue, the Company had approximately $95 million in cash, cash equivalents and investmen

Filing Documents

• rpid-20240110.htm (8-K) — 37KB
• ex991_prxrpidx20240110.htm (EX-99.1) — 17KB
• 0001380106-24-000009.txt ( ) — 194KB
• rpid-20240110.xsd (EX-101.SCH) — 2KB
• rpid-20240110_lab.xml (EX-101.LAB) — 26KB
• rpid-20240110_pre.xml (EX-101.PRE) — 13KB
• rpid-20240110_htm.xml (XML) — 3KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On January 10, 2024, Rapid Micro Biosystems, Inc. (the "Company") issued a press release announcing its preliminary unaudited revenue results and certain business highlights for the fourth quarter and full year ended December 31, 2023. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety. The information furnished under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as otherwise expressly stated in such filing.

01 Other Events

Item 8.01 Other Events. On January 10, 2024, the Company provided the following corporate updates: Growth Direct Rapid Sterility Application . The Company expects the commercial launch of the Growth Direct Rapid Sterility application by mid-year 2024. The Growth Direct Rapid Sterility application delivers time to organism detection in as little as 12 hours and final time-to-result in as little as one to three days. This capability represents a significant improvement over widely used traditional test methods, which generally require a 14-day endpoint incubation, and provides compelling differentiation when compared to current rapid sterility products. Fourth Quarter and Full Year 2023 Highlights. During the fourth quarter of 2023, the Company placed six new Growth Direct systems and completed nine validations. During the full year 2023, the Company placed 16 new Growth Direct systems and completed 18 validations. Growth Direct systems are now placed with 100% of commercially approved CAR-T therapy manufacturers. Fourth Quarter and Full Year 2023 Preliminary Unaudited Revenue. The Company currently expects total revenue of between $6.2 million and $6.4 million in the fourth quarter of 2023, representing growth of approximately 45% compared to the prior-year period. Full year 2023 total revenue is expected to be between $22.4 million and $22.6 million, representing growth of over 30% compared to the prior year. Cash Runway. Based on expected fourth quarter and full year 2023 preliminary unaudited revenue, the Company had approximately $95 million in cash, cash equivalents and investments as of December 31, 2023, which it expects to provide cash runway at least into the second half of 2026.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release of Rapid Micro Biosystems, Inc. dated January 10, 2024 104 Cover Page Interactive Data File (formatted as inline XBRL). ________________________________________________ Cautionary Statement Regarding Forward-Looking Statements This Current Report on Form 8-K includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding guidance on financial results for the fourth fiscal quarter and full year 2023; expectations regarding the Company's future revenue and growth; the Company's anticipated use of capital and ability to fund operations at least into the second half of 2026; expected placements of Growth Direct systems, anticipated timing of such placements and the impact on the Company's revenue; expectations regarding the Company's commercial execution for both products and services and improvements to the sales and marketing processes; expectations regarding the impact of macroeconomic uncertainty on the Company; customer interest in and adoption of the Company's Growth Direct system; the expected commercial launch of the Growth Direct Rapid Sterility application by mid-year 2024; customer interest in and adoption of the company's Growth Direct Rapid Sterility application; and the anticipated benefits of Growth Direct Rapid Sterility application for the Company's customers. In some cases, you can identify forward-looking statements by terminology such as "outlook," "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "predict," "pot

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RAPID MICRO BIOSYSTEMS, INC. Date: January 10, 2024 By: /s/ Sean Wirtjes Sean Wirtjes Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR